Disease · MONDO_0005231
Comparisons in its trials228
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 228
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| GZR 100 mg + EBR 50 mg +/- RBV vs Other GZR Regimen: Number of Participants Who Experienced a Drug-Related Serious Adverse Event (SAE) During the Long-Term Follow-Up | 1 of 1,909 | 1 of 526 | 2,435 | NCT01667081 | Trial comparisons |
| GZR 100 mg + EBR 50 mg +/- RBV vs Other GZR Regimen: Number of Participants Who Experienced an Event of Clinical Interest (ECI) During the Long-Term Follow-Up | 98 of 1,909 | 4 of 526 | 2,435 | NCT01667081 | Trial comparisons |
| GZR 100 mg + EBR 50 mg +/- RBV vs Other GZR Regimen: Number of Participants Who Experienced a Drug-Related Adverse Event (AE) During the Long-Term Follow-Up | 1 of 1,909 | 1 of 526 | 2,435 | NCT01667081 | Trial comparisons |
| Stage 1 Participants vs Stage 2 Participants: Number of Participants Discontinued From Study Treatment Due to Adverse Events (Stage 1 and Stage 2) | 76 of 1,302 | 142 of 1,128 | 2,430 | NCT00724893 | Trial comparisons |
| Mono-infected With HCV vs Co-infected With HCV and HIV: Number of Participants With Rapid Virologic Response After 4 Weeks of Treatment | 551 of 1,010 | 32 of 72 | 1,082 | NCT00724854 | Trial comparisons |
| Mono-infected With HCV vs Co-infected With HCV and HIV: Number of Participants Who Achieved Sustained Virologic Response (SVR) | 375 of 1,010 | 24 of 72 | 1,082 | NCT00724854 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Serious Adverse Events | 175 of 517 | 155 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Development of Hepatocellular Carcinoma (HCC) | 13 of 517 | 16 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Variceal Hemorrhage | 5 of 517 | 11 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Ascites | 32 of 517 | 27 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Presumed Hepatocellular Carcinoma (HCC) | 10 of 517 | 9 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Death From Any Cause | 31 of 517 | 22 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Spontaneous Bacterial Peritonitis | 3 of 517 | 3 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits | 57 of 517 | 52 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Hepatic Encephalopathy | 15 of 517 | 22 of 533 | 1,050 | NCT00006164 | Trial comparisons |
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points | 157 of 517 | 157 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: serious adverse events | 175 of 517 | 155 of 533 | 1,050 | NCT00006164 | Trial comparisons |
| SOF/VEL/VOX 8 Weeks vs SOF/VEL 12 Weeks: deaths from any cause | 0 of 501 | 0 of 440 | 941 | NCT02607800 | Trial comparisons |
| SOF/VEL/VOX 8 Weeks vs SOF/VEL 12 Weeks: serious adverse events | 15 of 501 | 7 of 440 | 941 | NCT02607800 | Trial comparisons |
| Placebo+Antiviral Therapy: DB Phase vs Eltrombopag+Antiviral Therapy: DB Phase: Number of Participants Who Prematurely Discontinued Antiviral Therapy in the DB Phase | 164 of 253 | 242 of 506 | 759 | NCT00529568 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005231/comparisons